Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 11

Results For "innovative"

1780 News Found

Kauvery Hospital sets new benchmark in high-risk cardiac care
Hospitals | April 04, 2026

Kauvery Hospital sets new benchmark in high-risk cardiac care

71-year-old high-risk patient with atrial fibrillation and ventricular tachycardia discharged next day


Concept Medical unveils landmark SirPAD trial at ACC 2026, advancing PAD treatment
Medical Device | April 03, 2026

Concept Medical unveils landmark SirPAD trial at ACC 2026, advancing PAD treatment

The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment


EMA moves to cut animal testing with “virtual control groups” in preclinical research
Policy | April 03, 2026

EMA moves to cut animal testing with “virtual control groups” in preclinical research

The approach, which could significantly reduce the number of rats used in certain dose-range finding studies


Glenmark Pharmaceuticals accelerates U.S. strategy with direct RYALTRIS distribution
News | April 02, 2026

Glenmark Pharmaceuticals accelerates U.S. strategy with direct RYALTRIS distribution

This marks a meaningful step in the company's continued expansion in the region


Lupin completes acquisition of VISUfarma
News | April 02, 2026

Lupin completes acquisition of VISUfarma

The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe


Biogen to buy Apellis Pharmaceuticals for $5.6B in rare disease and immunology push
News | April 02, 2026

Biogen to buy Apellis Pharmaceuticals for $5.6B in rare disease and immunology push

The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio


Lilly to acquire sleep drug biotech firm Centessa in $6.3 billion deal
News | April 01, 2026

Lilly to acquire sleep drug biotech firm Centessa in $6.3 billion deal

The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions


Sygnature Discovery appoints Susanne Back as Head of In Vivo Pharmacology
People | April 01, 2026

Sygnature Discovery appoints Susanne Back as Head of In Vivo Pharmacology

She brings 20 years of in vivo pharmacology experience across academia and industry, including senior scientific and leadership roles at Orion Pharma and Charles River


Bristol Myers Squibb reports positive phase 4 data on Cobenfy for schizophrenia patients
News | March 31, 2026

Bristol Myers Squibb reports positive phase 4 data on Cobenfy for schizophrenia patients

The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks


Allergan Aesthetics showcases breakthroughs at AAD 2026
Clinical Trials | March 31, 2026

Allergan Aesthetics showcases breakthroughs at AAD 2026

Allergan also presented new insights on the growing population of patients on GLP-1 agonists for weight loss who are seeking aesthetic treatments